This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
by Zacks Equity Research
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.
Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock
by Urmimala Biswas
Medtronic's Medical Surgical segment faces challenges in the third quarter due to shifts in U.S. distributor buying patterns.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Abivax SA Sponsored ADR (ABVX) have performed compared to their sector so far this year.
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
by Zacks Equity Research
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
AMN Stock Gains Following Q4 Earnings & Revenues Beat, Margins Down
by Zacks Equity Research
AMN Healthcare's dismal results in the majority of its segments led to a soft overall fourth-quarter performance.
ITGR Stock Declines Following Q4 Earnings Miss, Gross Margin Contract
by Zacks Equity Research
Integer Holdings' fourth-quarter results reflect robust sales from the majority of the product lines, along with continued product adoption.
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
by Zacks Equity Research
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
by Urmimala Biswas
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
Is it the Right Time to Hold EYE Stock in Your Portfolio Now?
by Zacks Equity Research
National Vision continues to draw investors' attention with its strategic transformation efforts, while positive industry trends should favor its growth.
PBH or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
SYK Trades Below 52-Week High: Should You Buy, Hold or Sell the Stock?
by Indrajit Bandyopadhyay
Stryker is gaining momentum with strong Q4 results, innovative medtech solutions and high-growth market expansion. But, is the stock still a buy? Find out the key factors at play.
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
by Zacks Equity Research
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.
DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand
by Zacks Equity Research
Robust segmental revenues drive DaVita's fourth-quarter 2024 performance despite a per-day decrease of the total U.S. dialysis treatments on a sequential basis.
Is Now the Right Time to Hold on to Charles River Stock?
by Zacks Equity Research
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down
by Zacks Equity Research
West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products segment.
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
by Zacks Equity Research
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract
by Zacks Equity Research
Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
by Zacks Equity Research
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Zacks.com featured highlights include Brinker International, Business First Bancshares, AZEK, Celestica and Boston Scientific
by Zacks Equity Research
Brinker International, Business First Bancshares, AZEK, Celestica and Boston Scientific have been highlighted in this Screen of The Week article.
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
by Urmimala Biswas
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
EMEA Expansion to Support BSX Stock Amid Fierce Competition
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
5 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility
by Santanu Roy
Invest in stocks of EAT, BFST, AZEK, CLS and BSX to tap their high efficiency levels.
ECL Stock Up in Pre-Market Following Q4 Earnings Beat, Margins Expand
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its fourth-quarter 2024 sales despite business challenges.
MDT Stock Trades Cheaper Than Peers Ahead of Q3 Earnings: Time to Buy?
by Urmimala Biswas
Medtronic expects its fiscal 2025 third-quarter revenues to reflect an unfavorable impact of 1% from currency translation.